Normobaric hyperoxia preconditioning ameliorates cisplatin nephrotoxicity: a pilot prospective case-control study

Aims: The aim of the present study was to examine whether preconditioning with normobaric hyperoxia would prevent cisplatin-induced nephrotoxicity in patients with solid tumor. Methods: Twenty-one adult patients with solid tumor treated with cisplatin were entered in this pilot and prospective study between Feb 2009 and Nov 2009. Inclusion criteria: the patients who treated with cisplatin due to cancer. Exclusion criteria: The patients who had chronic obstructive lung disease, pneumothorax, upper respiratory infection, fever, viral infection, history of seizure, pregnancy, optic nerve inflammation, history of ear surgery and history of heavy cigarette smoking were excluded from this study. Ten patients were exposed to pure oxygen via non-rebreathing reservoir mask which increased the provided oxygen rate to 60% oxygen for 2 hours at 48, 24 and 6 hours before intravenous administration of cisplatin. Venous blood samples were obtained from all patients for serum urea and creatinine (Cr) measurements as primary outcome on day 1 before and days 2 and 5 days after cisplatin exposures. The renal function was also measured with the glomerular filtration rate (GFR) estimated by the Cockcroft-Gault equation [GFR = (140-age) × (Wt in kg) × (0.85 if female) / (72 × Cr)]. Docetaxel (trade name Taxotere) was given 75 mg/m2 intravenous on day 1; consequently cisplatin was administered 50 mg/m2 at the second day and 2-3 L of normal saline was infused on the day of cisplatin administration. All patients received 5-FU 350 mg/m2 for five days after injection of cisplatin.

Baqiyatallah University of Medical Sciences